ADVISORSHARES PSYCHEDELICS ETF
Schedule of Investments
September 30, 2022 (Unaudited)
Investments | Shares | Value | ||||||
COMMON STOCKS – 90.5% | ||||||||
Biotechnology – 55.1% | ||||||||
ATAI Life Sciences NV (Germany)* | 190,600 | $ | 630,886 | |||||
Bright Minds Biosciences, Inc. (Canada)* | 285,278 | 350,892 | ||||||
Cybin, Inc. (Canada)*(a) | 1,439,433 | 696,685 | ||||||
Enveric Biosciences, Inc.*(a) | 78,354 | 330,654 | ||||||
GH Research PLC (Ireland)*(a) | 30,056 | 349,251 | ||||||
Intra-Cellular Therapies, Inc.* | 8,076 | 375,776 | ||||||
Mind Medicine MindMed, Inc.* | 59,952 | 209,832 | ||||||
PsyBio Therapeutics Corp.* | 2,583,122 | 243,976 | ||||||
Sage Therapeutics, Inc.* | 9,232 | 361,525 | ||||||
Seelos Therapeutics, Inc.* | 470,151 | 484,255 | ||||||
Small Pharma, Inc. (Canada)* | 2,000,937 | 230,208 | ||||||
Total Biotechnology | 4,263,940 | |||||||
Healthcare - Services – 10.1% | ||||||||
Field Trip Health & Wellness Ltd. (Canada)* | 429,851 | 60,136 | ||||||
Greenbrook TMS, Inc. (Canada)* | 117,428 | 310,010 | ||||||
Numinus Wellness, Inc. (Canada)* | 1,285,159 | 249,578 | ||||||
Reunion Neuroscience, Inc. (Canada)* | 110,152 | 160,822 | ||||||
Total Healthcare - Services | 780,546 | |||||||
Pharmaceuticals – 25.3% | ||||||||
Alkermes PLC* | 13,762 | 307,306 | ||||||
Compass Pathways PLC (United Kingdom)*(b) | 82,888 | 889,388 | ||||||
FSD Pharma, Inc., Class B (Canada)* | 452,529 | 380,124 | ||||||
Relmada Therapeutics, Inc.*(a) | 10,458 | 387,155 | ||||||
Total Pharmaceuticals | 1,963,973 | |||||||
Total Common Stocks | ||||||||
(Cost $12,778,613) | 7,008,459 | |||||||
MONEY MARKET FUND – 6.8% | ||||||||
BlackRock Liquidity Funds Treasury Trust Fund Portfolio, Institutional Class, 2.47%(c) | ||||||||
(Cost $528,663) | 528,663 | 528,663 | ||||||
REPURCHASE AGREEMENTS – 6.6%(d) | ||||||||
BofA Securities, Inc., dated 09/30/22, due 10/03/22, 2.94%, total to be received $13,547, (collateralized by various U.S. Government Agency Obligations, 4.13%, 9/30/27, totaling $13,815) | $ | 13,544 | 13,544 | |||||
Citibank NA, dated 09/30/22, due 10/03/22, 3.05%, total to be received $249,063, (collateralized by various U.S. Government Agency Obligations, 1.38%-4.50%, 4/15/25-12/1/48, totaling $254,195) | 249,000 | 249,000 | ||||||
RBC Dominion Securities, Inc., dated 09/30/22, due 10/03/22, 3.04%, total to be received $249,063, (collateralized by various U.S. Government Agency Obligations, 0.00%-6.00%, 8/15/25-8/20/52, totaling $253,980) | 249,000 | 249,000 | ||||||
Total Repurchase Agreements | ||||||||
(Cost $511,544) | 511,544 | |||||||
Total Investments – 103.9% | ||||||||
(Cost $13,818,820) | 8,048,666 | |||||||
Liabilities in Excess of Other Assets – (3.9%) | (305,108 | ) | ||||||
Net Assets – 100.0% | $ | 7,743,558 |
PLC - Public Limited Company
* | Non-income producing security. |
(a) | All or a portion of security is on loan. The aggregate market value of the securities on loan is $581,947; the aggregate market value of the collateral held by the fund is $700,855. The aggregate market value of the collateral includes non-cash U.S. Treasury securities collateral having a value of $189,311. |
(b) | American Depositary Receipt. |
(c) | Rate shown reflects the 7-day yield as of September 30, 2022. |
(d) | Collateral received from brokers for securities lending was invested in these short-term investments. |
ADVISORSHARES PSYCHEDELICS ETF
Schedule of Investments (continued)
September 30, 2022 (Unaudited)
For information on the Fund’s policies regarding the valuation of investments and other significant accounting policies, please refer to the Fund’s most recent semi-annual or annual financial statements.
Fair Value Measurements
The following is a summary of the inputs used, as of September 30, 2022, in valuing the Fund’s assets and liabilities carried at fair value. These inputs are summarized in three broad levels. Level 1 includes quoted prices in active markets for identical securities. Level 2 includes other significant observable inputs (including quoted prices for similar securities, interest rates, prepayment speeds and credit risk). Level 3 includes significant unobservable inputs (including the Fund’s own assumptions in determining the fair value of investments). The level assigned to the securities valuations may not be an indication of the risk or liquidity associated with investing in those securities.
Assets | Level 1 | Level 2 | Level 3 | Total | ||||||||||||
Common Stocks | $ | 7,008,459 | $ | - | $ | - | $ | 7,008,459 | ||||||||
Money Market Fund | 528,663 | - | - | 528,663 | ||||||||||||
Repurchase Agreements | - | 511,544 | - | 511,544 | ||||||||||||
Total | $ | 7,537,122 | $ | 511,544 | $ | - | $ | 8,048,666 |
Liabilities | Level 1 | Level 2 | Level 3 | Total | ||||||||||||
Swaps† | $ | - | $ | (390,615 | ) | $ | - | $ | (390,615 | ) |
† | Derivative instruments, including swap contracts, are valued at the net unrealized gain (loss) on the instrument. |
SUMMARY OF SCHEDULE OF INVESTMENTS
% of | ||||
Net Assets | ||||
Biotechnology | 55.1 | % | ||
Healthcare - Services | 10.1 | |||
Pharmaceuticals | 25.3 | |||
Money Market Fund | 6.8 | |||
Repurchase Agreements | 6.6 | |||
Total Investments | 103.9 | |||
Liabilities in Excess of Other Assets | (3.9 | ) | ||
Net Assets | 100.0 | % |
ADVISORSHARES PSYCHEDELICS ETF
Schedule of Investments (continued)
September 30, 2022 (Unaudited)
Total Return Swap contracts outstanding as of September 30, 2022:
Reference Entity | Annual Financing Rate Paid | Payment Frequency | Termination Date | Notional Amounts | Fair Value | Unrealized Appreciation/ (Depreciation) | ||||||||||||
Betterlife Pharma | - | - | 8/25/2026 | $ | 24,939 | $ | 15,619 | $ | (9,320 | ) | ||||||||
Core One Labs | - | - | 8/25/2026 | 99,949 | 41,535 | (58,414 | ) | |||||||||||
Empower Clinics | - | - | 8/25/2026 | 30,268 | - | (30,268 | ) | |||||||||||
Mindcure Health | - | - | 8/25/2026 | 30,395 | 7,930 | (22,465 | ) | |||||||||||
Mindset Pharma | - | - | 8/25/2026 | 76,703 | 47,216 | (29,487 | ) | |||||||||||
Numinus Wellness | - | - | 8/25/2026 | 27,601 | 6,525 | (21,076 | ) | |||||||||||
Optimi Health | - | - | 8/25/2026 | 21,689 | 8,676 | (13,013 | ) | |||||||||||
Psyched Wellness | - | - | 8/25/2026 | 23,201 | 11,008 | (12,193 | ) | |||||||||||
Red Light Holland | - | - | 8/25/2026 | 19,988 | 8,137 | (11,851 | ) | |||||||||||
Revive Therapeutics | - | - | 8/25/2026 | 60,723 | 27,840 | (32,883 | ) | |||||||||||
Tryp Therapeutics | - | - | 8/25/2026 | 39,076 | 16,800 | (22,276 | ) | |||||||||||
Wesana Health | - | - | 8/25/2026 | 134,195 | 6,826 | (127,369 | ) | |||||||||||
Net Unrealized Depreciation | $ | (390,615 | ) |
Cowen acts as the counterparty to the total return swap contracts listed above. The Fund either receives fees from, or pays fees to, the counterparty, depending upon the total return of the benchmark, and the agreed-upon floating financing rate.